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Abstract
To guide health care professionals in Belgium in selecting the appropriate antiepileptic drugs (AEDs) for their epilepsy 
patients, a group of Belgian epilepsy experts developed recommendations for AED treatment in adults and children (initial 
recommendations in 2008, updated in 2012). As new drugs have become available, others have been withdrawn, new indi-
cations have been approved and recommendations for pregnant women have changed, a new update was pertinent. A group 
of Belgian epilepsy experts (partly overlapping with the group in charge of the 2008/2012 recommendations) evaluated 
the most recent international guidelines and relevant literature for their applicability to the Belgian situation (registration 
status, reimbursement, clinical practice) and updated the recommendations for initial monotherapy in adults and children 
and add-on treatment in adults. Recommendations for add-on treatment in children were also included (not covered in the 
2008/2012 publications). Like the 2008/2012 publications, the current update also covers other important aspects related to 
the management of epilepsy, including the importance of early referral in drug-resistant epilepsy, pharmacokinetic proper-
ties and tolerability of AEDs, comorbidities, specific considerations in elderly and pregnant patients, generic substitution 
and the rapidly evolving field of precision medicine.
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Introduction
Epilepsy is one of the most common neurological diseases, 
affecting approximately 50,000,000 people worldwide [1]. 
In Belgium, an estimated 100,000 people are living with epi-
lepsy [2]. The disease is defined by the occurrence of at least 
two unprovoked seizures more than 24 h apart or one unpro-
voked seizure and a high risk of recurrence (at least 60%), or 
by the diagnosis of an epilepsy syndrome [3]. In 2017, the 
International League Against Epilepsy (ILAE) updated their 
classification of seizure types, using seizure onset as their 
basis. They distinguish focal-onset seizures (originating in 
one hemisphere, formerly called partial seizures), general-
ized-onset seizures (originating in both hemispheres, e.g., 
absences, generalized tonic–clonic, atonic and myoclonic 
seizures) and seizures of unknown onset [4]. Seizures that 
start focally and spread to bilateral tonic–clonic movements 
(previously called secondarily generalized tonic–clonic sei-
zures) are referred to as focal-to-bilateral tonic–clonic sei-
zures [4].
Once a diagnosis of epilepsy is confirmed, most patients 
are treated with antiepileptic drugs (AEDs). Currently, 
more than 20 different AEDs are registered in Belgium [5]. 
While this large number allows tailoring treatment to indi-
vidual patients’ needs, it makes selection of the most suit-
able compound complex. The choice of an AED depends on 
the patient’s seizure type, age, sex, childbearing potential, 
comorbidities and concomitant medications, and the drug’s 
adverse effect and interaction profiles (Fig. 1). To guide 
health care professionals in Belgium in making this choice, 
a group of experts developed recommendations for the man-
agement of epilepsy in adults and children in general neuro-
logical practice in Belgium in 2008 [6] and updated these in 
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2012 [7]. Since then, new indications of previously available 
AEDs have been approved (e.g., monotherapy and changes 
in the lower age limit for lacosamide [8, 9]), new AEDs 
have become available (e.g., perampanel and brivaracetam 
[10, 11]) and others have disappeared from the market (e.g., 
pheneturide and retigabine [12, 13]). Changes in clinical 
practice are also warranted for certain subpopulations, espe-
cially pregnant women. A new update of the recommenda-
tions therefore seemed pertinent.
Methodology
The initial recommendations for the management of epi-
lepsy in general neurological practice in Belgium [6] and the 
updated recommendations [7] were based on guidelines by 
the ILAE [14], the American Academy of Neurology (AAN 
[15, 16]), the Scottish Intercollegiate Guidelines Network 
(SIGN [17]) and the United Kingdom National Institute for 
Health and Care Excellence (NICE [18]), and relevant arti-
cles on controlled clinical trials published after the cut-off 
dates used in these guidelines. This resulted in recommenda-
tions for initial monotherapy in adults and children and for 
add-on treatment in adults [6, 7].
In October 2019, a group of Belgian epilepsy experts 
(partly overlapping with the group in charge of the 
2008/2012 recommendations) convened to discuss the 
strategy to update the current recommendations. Following 
this first meeting, the ILAE, AAN, SIGN and NICE websites 
were searched for updates to their guidelines. The AAN pub-
lished updated guidelines for the treatment of new-onset and 
drug-resistant epilepsy in 2018 [19, 20], SIGN published 
updated guidelines for the management of epilepsy in adults 
in 2015 with revisions in 2018 [21] and NICE published 
updated guidelines for the management of epilepsy in chil-
dren and adults in 2012 with a last revision in 2020 [22]. 
No updates to the ILAE guidelines (encompassing the gen-
eral adult or pediatric patient population) were found but 
an updated evidence review of AED efficacy and effective-
ness as initial monotherapy was published in 2013 [23], and 
a report on the management of epilepsy during pregnancy 
in 2019 [24]. As the last fully updated guidelines (AAN) 
were based on a systematic literature search up to November 
2015, the information extracted from the different guide-
lines was supplemented with information from (systematic) 
reviews and/or meta-analyses on AED treatment (comparing 
multiple AEDs) published between January 2016 and Febru-
ary 2020, retrieved by searching PubMed and the Cochrane 
Library.
The experts evaluated the updated AAN, SIGN and NICE 
guidelines, the ILAE evidence review and the relevant pub-
lished articles for their applicability to the Belgian situa-
tion (registration status, reimbursement, clinical practice) 
and prepared an update of the recommendations for initial 
Fig. 1  Epilepsy treatment pathway. AED, antiepileptic drug. aPrompt 
referral of patients with drug-resistant epilepsy or certain com-
plex epilepsy syndromes is crucial to improve a patient’s chances to 
achieve seizure control and avoid life-long sequelae. bNeurostimula-
tory approaches include vagus nerve and deep brain stimulation; die-
tary approaches include ketogenic and modified Atkins diet
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monotherapy in adults and children and add-on treatment in 
adults. In addition, recommendations for add-on treatment 
in children were included, which were not covered in the 
2008/2012 publications.
The following criteria were used to prepare the treatment 
recommendations in this update:
1. The AED is registered and reimbursed in Belgium [5, 
25]. Remarks are included for drugs that were proven to 
be effective for a certain indication but are currently not 
registered or reimbursed for that indication in Belgium.
2. The AEDs with the highest level of evidence for efficacy 
across the different guidelines or evidence reviews are 
recommended as first choice. As the different guidelines 
do not all use the same method to rate the evidence in 
the studies they reviewed, no levels of evidence for effi-
cacy are stated in the current recommendations.
3. In the rare cases where the level of evidence for differ-
ent AEDs was the same or where evidence was limited, 
recommendations were based on a consensus among the 
authors.
The same definitions as in the 2008/2012 recommenda-
tions were used [6, 7]:
– First choice: First treatment choice in a patient without 
any specific factors precluding the use of this AED (e.g., 
comorbidity, concomitant medication).
– Alternative first choice: AED recommended when cer-
tain patient-related factors (e.g., comorbidity, concomi-
tant medication) or AED-related factors (e.g., interaction 
potential, contraindications, adverse effect profile) pre-
clude the use of the first-choice AED.
Wherever possible, the newly developed ILAE 2017 clas-
sification of seizure types was used [4].
Recommendations for treatment
Initial monotherapy in adults and children
Focal‑onset seizures
Registered and reimbursed treatment options for monother-
apy of focal-onset seizures (including focal-to-bilateral sei-
zures) in adults and children in Belgium are carbamazepine, 
lamotrigine (age ≥ 12 years), levetiracetam (≥ 16 years), 
oxcarbazepine (≥ 6 years), phenobarbital, phenytoin, primi-
done, topiramate (≥ 6 years) and valproate (Table 1). Since 
the 2012 publication, pheneturide was withdrawn [12] and 
lacosamide was approved for monotherapy of focal-onset 
seizures (≥ 4 years [8, 9]) but is not reimbursed for this 
indication. Similarly, gabapentin is approved but not reim-
bursed for monotherapy of focal-onset seizures (≥ 12 years) 
(Table 1).
Of these options, carbamazepine, lamotrigine, leveti-
racetam and oxcarbazepine are recommended as first choice, 
while topiramate and valproate are suitable alternative first 
choices (except for valproate in women/girls of childbearing 
potential) (Table 2) [20–23, 26, 27]. Since approximately 
50% of patients respond to the first monotherapy [28], it 
should be appropriately chosen including tolerability profile, 
risk for future pregnancies and drug interactions. Hence, 
phenytoin and phenobarbital should not be first choices, 
despite being approved and reimbursed (author consensus). 
Evidence from randomized trials is more limited in chil-
dren [29] and the aforementioned age restrictions should 
be taken into account in the pediatric recommendations 
(e.g., levetiracetam is not licensed as monotherapy in chil-
dren < 16 years). Compared to carbamazepine, which has 
been used for over 50 years, several of the newer AEDs (e.g., 
lamotrigine, levetiracetam and oxcarbazepine) have a more 
favorable pharmacokinetic profile and lamotrigine is better 
tolerated [30].
Generalized‑onset seizures
Generalized-onset seizures include motor seizures (e.g., 
tonic–clonic, myoclonic, atonic) and non-motor or absence 
seizures [4]. Not all AEDs indicated for generalized-onset 
seizures cover all these seizure types. Registered and reim-
bursed treatment options for monotherapy of generalized-
onset tonic–clonic seizures in adults and children in Belgium 
are carbamazepine, lamotrigine (age ≥ 12 years), phenobar-
bital, phenytoin, primidone, topiramate (≥ 6 years) and val-
proate (Table 1). Since the 2012 publication, no new AEDs 
have become available as monotherapy for this indication in 
Belgium. Ethosuximide (≥ 3 years), lamotrigine (≥ 2 years) 
and valproate are registered and reimbursed as monotherapy 
for absence seizures (Table 1).
Valproate, phenobarbital and primidone are available for 
the treatment of myoclonic and/or other generalized seizure 
types (e.g., atonic).
For generalized-onset tonic–clonic seizures, valproate 
is recommended as first choice (except in women/girls of 
childbearing potential); lamotrigine and topiramate are 
valuable alternatives, however, lamotrigine can aggra-
vate myoclonic seizures (e.g., in patients with Juvenile 
Myoclonic Epilepsy [JME]) (Table 2) [21–23, 27, 31, 32]. 
Levetiracetam is effective as monotherapy for generalized-
onset tonic–clonic seizures [27, 31, 32] but is currently not 
reimbursed for this seizure type in Belgium. Carbamaz-
epine can also be considered as monotherapy for general-
ized-onset tonic–clonic seizures but is not effective against 
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Table 2  Recommendations for initial monotherapy and add-on therapy for seizures in adults and children
First choice refers to first treatment choice in a patient without any specific factors precluding the use of this antiepileptic drug (AED). Alterna-
tive first choice refers to AEDs recommended when certain patient- or AED-related factors preclude the use of the first-choice AED
The efficacy of older AEDs in add-on treatment is considered to be established during long-term clinical experience
AED antiepileptic drug, JME juvenile myoclonic epilepsy, m month of age, NR AED not reimbursed for the specified treatment type/indication, 











Lamotrigine (≥ 12 y)
Levetiracetam (≥ 16 y)
Oxcarbazepine (≥ 6 y)
Topiramate (≥ 6 y)
Valproate
Brivaracetam (≥ 4 y)
Carbamazepine
Gabapentin (≥ 6 y)
Lacosamide (≥ 4 y)
Lamotrigine (≥ 2 y)
Levetiracetam (≥ 1 m)
Oxcarbazepine (≥ 6 y)
Perampanel (≥ 12 y)
Pregabalin (≥ 18 y)
Tiagabine (≥ 12 y)
Topiramate (≥ 2 y)
Valproate
Lamotrigine and levetiracetam are pre-
ferred over carbamazepine in older 
patients due to their better tolerability 
and lower risk of drug–drug interac-
tions [80, 81]
Tiagabine is rarely used; gabapentin 
and pregabalin are infrequently used
Brivaracetam, lacosamide and per-
ampanel are only reimbursed after 
failure of at least three AEDs
Clobazam can be considered as add-on 
treatment (but is not reimbursed for 
epilepsy) [19, 22]
Vigabatrin can also be used as add-on 
treatment but only as last choice 
because of its unfavorable safety 
profile
Avoid valproate in pregnant women/
women of childbearing potential
Generalized-onset tonic–
clonic seizures, (tonic 
and atonic seizures)
Valproate Carbamazepine
Lamotrigine (≥ 12 y)
Topiramate (≥ 6 y)
Carbamazepine
Lamotrigine (≥ 2 y)
Levetiracetam (NR; ≥ 12 y)
Topiramate (≥ 2 y)
Valproate
Carbamazepine can be considered (for 
tonic–clonic seizures) but should be 
avoided if absence or myoclonic sei-
zures are present or JME is suspected 
[22, 23]
Lamotrigine can aggravate myoclonic 
seizures [22]
Levetiracetam is also effective as 
monotherapy for generalized-onset 
seizures [27, 31, 32] but is currently 
only licensed as add-on for this 
seizure type
Clobazam could be considered as add-
on treatment (not reimbursed) [22]
Avoid valproate in pregnant women/
women of childbearing potential
Absence seizures Ethosuximide (≥ 3y)
Valproate
Lamotrigine (≥ 2 y) Ethosuximide (≥ 3 y)
Lamotrigine (≥ 2 y)
Valproate
Carbamazepine, gabapentin, oxcar-
bazepine, phenobarbital, phenytoin, 
pregabalin, tiagabine and vigabatrin 
may aggravate absence seizures [22, 
23]
Clobazam and clonazepam could be 
considered as add-on treatment (not 
reimbursed) [22]
Avoid valproate in pregnant women/
women of childbearing potential
Myoclonic seizures Valproate Levetiracetam (≥ 12 y; in JME)
Valproate
Carbamazepine, gabapentin, lamo-
trigine, oxcarbazepine, phenytoin, 
pregabalin, tiagabine and vigabatrin 
may aggravate myoclonic seizures 
[22, 23]
Clobazam and clonazepam could be 
considered as add-on treatment (not 
reimbursed) [22]
Avoid valproate in pregnant women/
women of childbearing potential
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other generalized-onset seizure types and can aggravate 
absences, myoclonic and tonic/atonic seizures [22, 23].
For absence seizures, ethosuximide and valproate 
are recommended as first choice (except for valproate in 
women/girls of childbearing potential) and lamotrigine as 
alternative first choice (Table 2) [20–23, 29, 31, 33]. For 
myoclonic and tonic/atonic seizures, valproate is recom-
mended as first choice (except in women of childbearing 
potential) [22, 34]. Levetiracetam could be considered 
as alternative for myoclonic seizures [22, 34], although 
it is not registered for monotherapy for this seizure type 
(Table 2).
Notably, carbamazepine, gabapentin, oxcarbazepine, phe-
nobarbital, phenytoin, pregabalin, tiagabine and vigabatrin 
may trigger or exacerbate myoclonic and/or absence seizures 
(Table 2) [22, 23].
Seizures of unknown onset
If the seizure type has not been established before starting 
AED treatment, a broad-spectrum AED (effective against the 
most common seizure types, such as valproate, lamotrigine, 
levetiracetam or topiramate) can be used (author consensus).
Add‑on treatment in adults and children
If the AED chosen for initial monotherapy is ineffective in 
controlling seizures, a second AED is typically selected for 
either substitution monotherapy (preferred option) or add-on 
therapy (Fig. 1) [21, 22, 35]. Failure of a second AED may 
require additional trials of various combination therapies 
[21, 22, 35]. The choice of add-on AEDs depends on the 
same compound- and patient-related factors as those impact-
ing the choice of the initial AED, and on the potential for 
interactions between the compounds. An increasing number 
of new AEDs, with different mechanisms of action, better 
pharmacokinetic profiles and better tolerability compared to 
the older AEDs have been licensed for add-on therapy in the 
last decades [36, 37]. “Rational polytherapy” relies on com-
bining AEDs with complementary mechanisms of action 
that may work synergistically to maximize efficacy and mini-
mize toxicity. Clinical trials and observational studies have 
shown that combinations of drugs with the same mecha-
nism of action (e.g., sodium channel blockers) are typically 
associated with higher rates of adverse events and treatment 
discontinuation [35, 38]. Clinical studies have shown syn-
ergistic interactions in terms of efficacy for the combination 
of valproate and lamotrigine, while for other combinations 
clinical evidence is limited [35, 38]. Therefore, the choice 
of AEDs in add-on therapy is still made on a case-by-case 
basis.
Focal‑onset seizures
Registered and reimbursed AEDs for add-on treatment 
of focal-onset seizures in adults and children in Belgium 
are brivaracetam (age ≥ 4 years), carbamazepine, gabap-
entin (≥ 6 years), lacosamide (≥ 4 years), lamotrigine 
(≥ 2 years), levetiracetam (≥ 1 month), oxcarbazepine 
(≥ 6  years), perampanel (≥ 12  years), phenobarbital, 
phenytoin, pregabalin (≥ 18 years), primidone, tiagabine 
(≥ 12 years), topiramate (≥ 2 years), valproate and vigaba-
trin (last choice) (Table 1).
Changes in registration or reimbursement status of 
drugs used as add-on therapy for focal-onset seizures 
after the 2012 recommendations include the registration 
of brivaracetam and perampanel [10, 11], an extension of 
the lower age limit for lacosamide (from 16 to 4 years [8]) 
and the withdrawal of pheneturide and retigabine [12, 13].
AEDs recommended for add-on therapy of focal-onset 
seizures are brivaracetam, carbamazepine, gabapentin, 
lacosamide, lamotrigine, levetiracetam, oxcarbazepine, 
perampanel, pregabalin (adults only), tiagabine, topira-
mate and valproate (except for women/girls of child-
bearing potential for the latter) (Table 2) [19, 21, 22, 29, 
39–42]. The benzodiazepine clobazam can also be con-
sidered in patients 6 years or older (but is not reimbursed 
for epilepsy treatment) [19, 22]. Brivaracetam, lacosamide 
and perampanel are only reimbursed after failure of at least 
three AEDs.
Generalized‑onset seizures
Registered and reimbursed AEDs for add-on treatment of 
generalized-onset seizures in adults and children in Belgium 
did not change since the 2012 recommendations; reimbursed 
compounds are carbamazepine, ethosuximide (≥ 3 years), 
lamotrigine (≥ 2 years), levetiracetam (for JME, ≥ 12 years), 
phenobarbital, phenytoin, primidone, topiramate (≥ 2 years) 
and valproate (Table 1). In addition, levetiracetam and 
perampanel are registered but not reimbursed for add-on 
treatment of generalized-onset tonic–clonic seizures in 
individuals ≥ 12 years.
Lamotrigine, topiramate and valproate are recommended 
as add-on treatment for generalized-onset tonic–clonic sei-
zures in adults and children (taking into account the afore-
mentioned age restrictions); levetiracetam and clobazam 
are also options (but are not reimbursed for this indica-
tion) (Table 2) [19, 21, 22]. Carbamazepine can be con-
sidered for generalized-onset tonic–clonic seizures (but 
should be avoided with other generalized seizure types). 
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Recommendations for other generalized-onset seizure types 
are summarized in Table 2.
Childhood epilepsy syndromes
Table 3 summarizes treatment options in selected epilepsy 
syndromes in children: simple febrile seizures [43, 44], 
childhood absence epilepsy [33, 45], childhood epilepsy 
with centro-temporal spikes [22, 23, 43], electrical sta-
tus epilepticus during sleep [46], West syndrome [22, 43, 
44, 47, 48], Dravet syndrome [49], Lennox–Gastaut syn-
drome [50] and neonatal-onset epilepsies related to path-
ogenic variants in potassium and sodium channel genes 
KCNQ2, SCN2A, SCN8A [51, 52]. For most of these syn-
dromes, referral to a tertiary pediatric epilepsy specialist 
is recommended.
Specific considerations
Drug‑resistant epilepsy and the importance of early 
referral
Around 30% of patients are refractory to AED treatment 
[53–55]. The ILAE’s consensus definition of drug-resist-
ant (or refractory) epilepsy is “failure of adequate trials 
of two tolerated and appropriately chosen and used AED 
schedules (whether as monotherapies or in combination) to 
achieve sustained seizure freedom” [56]. ILAE’s consensus 
definition may help non-specialists recognize drug-resist-
ant patients and ensure their prompt referral to tertiary care 
centers for expert evaluation and/or surgery (Fig. 1) [56]. 
Early referral of patients with drug-resistant epilepsy or with 
complex epilepsy syndromes (e.g., epileptic spasms [West 
syndrome], Dravet syndrome, continuous spikes and waves 
during slow sleep, tuberous sclerosis complex) is paramount 
to improve patients’ chances to achieve seizure control and 
avoid impairment of neurological and cognitive development 
in children, irreversible psychological and social problems, 
Table 3  Childhood epilepsy syndromes
Recommendations are based on author consensus
a Sulthiame is registered and reimbursed for some epilepsy indications in Belgium but is not available on the Belgian market and has to be 
ordered from abroad
b Cannabidiol is currently only available as non-reimbursed magistral preparation in Belgium
c Fenfluramine is not yet registered in Europe
d Choice of treatment depends on the nature of the mutation (gain-of-function versus loss-of-function)
Syndrome First line Second line Avoid
Simple febrile seizures [43, 44] None Valproate
Levetiracetam
Childhood absence epilepsy [33, 45] Ethosuximide Valproate
(Lamotrigine)
Carbamazepine, gabapentin, oxcarbazepine, 
phenobarbital, phenytoin, tiagabine and 
vigabatrin [22, 23]
Childhood epilepsy with centro-temporal 





Continuous spikes and waves during slow 
sleep (CSWS)/Electrical status epilepti-





West syndrome (infantile spasms) [22, 43, 
44, 47, 48]
ACTH/prednisolone + vigabatrin Topiramate
Benzodiazepines
Valproate




Sodium channel blockers (e.g., carbamaz-
epine)





Carbamazepine, oxcarbazepine, phenytoin, 
tiagabine
KCNQ2, SCN2A, SCN8A-related neonatal-
onset  epilepsiesd [51, 52]
Carbamazepine Phenytoin
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life-long disability and premature death [57, 58]. A recent 
systematic review showed that a shorter duration of epilepsy 
was significantly associated with a better seizure outcome 
after resective epilepsy surgery [59]. Aside from surgery, 
epilepsy centers can offer specialized diagnostic and thera-
peutic approaches that may identify the underlying cause 
of apparent or real drug resistance (e.g., non-adherence to 
medication, misdiagnosis, inadequate dosing, life style fac-
tors) and lead to seizure freedom in patients initially consid-
ered drug resistant (Fig. 1) [57, 58].
To treat drug-resistant epilepsy, non-AED treatment 
options can also be considered, including neurostimulatory 
approaches (e.g., vagus nerve stimulation [VNS] or deep 
brain stimulation [DBS]), ketogenic or modified Atkins 
diet and various complementary and behavioral approaches 
(Fig. 1) [21, 22, 53, 57, 58]. VNS can be considered in 
patients who are ineligible for resective surgery or for whom 
surgery failed. It has been shown to reduce seizure frequency 
in adults and children, and has shown mild and mostly tem-
porary stimulation-related side effects that are different from 
common side effects of AEDs [60, 61]. DBS of the anterior 
nucleus of the thalamus (ANT-DBS) is an alternative neu-
rostimulation modality that has shown long-term efficacy in 
drug-resistant patients [60, 62]. ANT-DBS has been shown 
to be well tolerated; most complications are related to the 
implantation technique. In patients with cognitive decline 
and mood disorders, caution is warranted [60, 62].
The ketogenic diet is a valid treatment option in children 
and adults with refractory epilepsy [61, 63]. It should be 
offered not as a last treatment option but earlier in the treat-
ment flow chart. In some conditions, such as glucose trans-
porter 1 (GLUT1) deficiency, and in some mitochondrial 
disorders, it is first-line treatment [61, 63]. The ketogenic 
diet is also increasingly being used in refractory status epi-
lepticus treatment and in some severe inflammatory epilep-
sies (e.g., new-onset refractory status epilepticus [NORSE]) 
[63]. In addition, immunotherapy has shown promise as 
adjunctive treatment in rare cases of autoimmune epilepsy, 
especially cases of NORSE. In particular, patients with 
febrile infection-related epilepsy syndrome (FIRES) benefit 
from targeted immunotherapy with anakinra (an interleu-
kin-1 receptor antagonist) after failure of standard immune 
therapy such as steroids or intravenous immunoglobulins 
[64–66].
Cannabidiol has shown efficacy comparable to other 
AEDs, but only in children with drug-resistant Dravet or 
Lennox–Gastaut syndrome [67]. Pharmacies in Belgium 
are now allowed to prepare and dispense medicinal prod-
ucts containing cannabidiol using a magistral formula 
[68]. In September 2019, one commercial cannabidiol-
containing drug (Epidyolex, GW Pharma [International] 
B.V.) was approved by the European Medicines Agency 
as add-on therapy of seizures associated with Dravet or 
Lennox–Gastaut syndrome, in conjunction with clobazam, 
in children ≥ 2 years old [69]. This drug is not yet available 
in Belgium and magistral preparations are not reimbursed.
Pharmacokinetic properties and pharmacokinetic 
interaction profile
Given that many epilepsy patients require life-long treat-
ment, take more than one AED and may take contraceptives 
or other drugs for diseases related or unrelated to epilepsy, it 
is important to minimize the risk of pharmacokinetic inter-
actions when selecting AEDs. Pharmacokinetic interactions 
may alter plasma concentrations of AEDs and other drugs by 
affecting absorption, transport, distribution (plasma protein 
binding), metabolism and/or renal elimination [70–72]. This 
may result in reduced efficacy or tolerability.
Several newer AEDs (particularly brivaracetam, gabapen-
tin, lacosamide and levetiracetam, Table 1) have a lower pro-
pensity of interactions because they do not induce or inhibit 
liver enzymes. The older AEDs, particularly hepatic enzyme 
inducers (e.g., carbamazepine, phenobarbital, phenytoin and 
primidone) and inhibitors (e.g., valproate) have a higher pro-
pensity for pharmacokinetic interactions (Table 1) [70–72].
Tolerability
Since efficacy of the newer generation AEDs has not 
improved substantially compared to the older AEDs, tol-
erability and safety are often the driving factors in select-
ing the optimal AED for a patient [73]. Common adverse 
events reported after AED use include dizziness, somno-
lence, fatigue, headache and gastrointestinal disturbances 
[27, 73, 74]. Long-term use of some AEDs (most notably, 
but not exclusively, enzyme inducers) has been associated 
with reduced bone mineral density and osteoporosis [75, 
76]. Therefore, osteodensitometry and other tests of bone 
metabolism, as well as dietary and lifestyle advice to mini-
mize the risk of osteoporosis are recommended with long-
term AED use [21, 22]. Table 1 includes a summary of the 
most common adverse effects (occurring in more than 10% 
of patients as listed in the summaries of product charac-
teristics [SmPCs]) and other important adverse events (as 
listed in the special warnings and precautions for use in the 
SmPCs). Detailed information can be found in the SmPCs 
or recent reviews [73, 74].
Comorbidity
Several central nervous system-related and other diseases, 
including depression, anxiety, dementia, migraine, heart 
disease, peptic ulcers and arthritis are more common in epi-
lepsy patients than in the general population [77]. The pres-
ence of concomitant disease is an important determinant in 
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the choice of AEDs since certain AEDs are contra-indicated 
or require special precautions in some of these conditions. 
More information on this topic can be found in the SmPCs; 
a summary is presented in Table 1.
Elderly
Causes for new-onset seizures in people older than 60 years 
include cerebrovascular diseases, high blood pressure, dia-
betes and dementia [78, 79]. Because of the high prevalence 
of these and other comorbid conditions, polypharmacy and a 
higher likelihood of dose-related and idiosyncratic adverse 
effects in the elderly population, selecting the optimal AED 
for elderly patients is challenging.
Focal-onset seizures with impaired awareness are the 
most common seizure type in people over 60 years [78]. For 
this seizure type, the first-choice AEDs for monotherapy in 
elderly patients are lamotrigine and levetiracetam; gabapen-
tin and lacosamide can be considered as alternatives (but are 
not reimbursed as monotherapy in Belgium) [20, 21, 23, 80, 
81]. Of note, carbamazepine has a poor tolerability profile 
in elderly people [78, 80, 81].
Pregnancy
AED use during pregnancy is of concern since AEDs can 
be transferred to the fetus via the placenta, which can result 
in fetal growth restriction, major congenital malforma-
tions (e.g., neural tube defects and cardiac anomalies) and 
impaired cognitive development in the child [24, 82–86]. 
These risks should be balanced against those associated with 
uncontrolled seizures (particularly generalized tonic–clonic 
seizures) [24].
Among all AEDs, prenatal exposure to valproate is asso-
ciated with the highest risk of major congenital malforma-
tions, delayed early cognitive skills and neurodevelopmental 
disorders (e.g., autistic spectrum disorder) [24]. Despite pre-
vious efforts to better inform women about these risks and 
discourage valproate use in girls and women, information 
was not sufficiently reaching patients [87, 88]. Therefore, 
the European Commission issued new legally binding meas-
ures in 2018 to avoid in utero exposure to valproate [89]. 
Valproate is now contraindicated in pregnant women unless 
there is no other effective treatment available. In girls and 
women of childbearing potential, valproate can only be used 
if conditions of a new pregnancy prevention program are met 
[89]. If valproate is the only effective treatment (which is 
more likely when treating generalized epilepsies), the dose 
should be kept as low as possible, because malformation 
rate is dose-dependent. The malformation rate with a daily 
dose < 650 mg is comparable to that with high doses of car-
bamazepine or lamotrigine [83].
Lamotrigine and levetiracetam are first-choice treatment 
options in pregnant women (and women of childbearing 
potential) because they carry the lowest risk of major con-
genital malformations and have no known impact on neu-
robehavioral development (although data for levetiracetam 
are still limited) [24]. Carbamazepine is recommended as 
alternative first choice; it shows higher malformation rates 
than lamotrigine and levetiracetam but no impact on neu-
rodevelopment [24]. Oxcarbazepine could also be consid-
ered; malformation rates are low but data on neurobehavioral 
development are sparse [24].
Importantly, blood drug levels should be monitored 
because pregnancy can have a major impact on pharmacoki-
netic properties of AEDs (e.g., altered absorption, increased 
distribution volume and renal excretion, and induction of 
hepatic metabolism). Lamotrigine, levetiracetam and oxcar-
bazepine serum concentrations decline most markedly, and 
dose adjustments may be necessary during pregnancy and 
postpartum [24].
Generic substitution
While generic AEDs are considered bioequivalent with the 
original brand name products, there are conflicting reports 
about the effect of switching from brand name to generic or 
among generic AEDs on seizure control, adverse effects, 
health care utilization and adherence [90–92]. The Belgian 
Center for Pharmacotherapeutic Information designates all 
AEDs as “no switch”, indicating that switching between 
brands and/or generics is not recommended [5]. When a 
patient is successfully treated with a particular brand of 
AED, treatment should be continued with that brand. 
When initiating treatment, the choice between prescribing 
a generic or brand-name AED should consider the likeli-
hood of a continuous supply of the compound from the same 
manufacturer. Importantly, supply problems are a reality for 
several generics in Belgium [93] and may make health care 
professionals reluctant to prescribe generic AEDs.
Precision medicine/personalized treatment
In recent years, great progress has been made in identi-
fying genetic causes of epilepsy and understanding the 
molecular mechanisms underlying its pathophysiology 
[51, 94]. This has allowed the identification of potential 
therapeutic targets and has helped select the most effective 
treatment for individual patients (personalized treatment or 
precision medicine). Well-established approaches of pre-
cision medicine include a ketogenic diet in patients with 
GLUT1 deficiency, vitamin B6 in pyridoxine-dependent 
epilepsy, sodium channel blockers (e.g., carbamazepine) 
in patients with neonatal-onset epilepsy due to mutations 
in potassium or sodium channel genes (KCNQ2, SCN2A, 
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SCN8A), avoiding sodium channel blockers in Dravet 
syndrome (characterized by loss-of-function mutations 
in the sodium channel gene SCN1A), and mTOR inhibi-
tors in mTORopathies (e.g., everolimus to treat focal sei-
zures associated with tuberous sclerosis complex) [51, 
94]. Importantly, different mutations in the same gene 
may have opposite effects and require opposite treatment 
approaches. For instance, sodium channel blockers only 
work for KCNQ2 loss-of-function, and SCN2A and SCN8A 
gain-of-function mutations [51, 95]. It is, therefore, crucial 
that treatment strategies are defined after expert multidis-
ciplinary review of pathogenic variants. With an increas-
ing number of targets and drugs being identified, the field 
of precision medicine is rapidly evolving and may contrib-
ute substantially to the advancement of epilepsy treatment.
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